LV11619A - 7-(Ú1a,5a,6a¾-amino-3-azabicikloÚ3.1.0¾heks-3-il)-6-fluor-1-(2,4-difluor-fenil)-1,4-dihidro-4-okso-1,8-naftiridin-3-karbonskabes metansulfonskabes sals jauna kristaliska modifikacija - Google Patents

7-(Ú1a,5a,6a¾-amino-3-azabicikloÚ3.1.0¾heks-3-il)-6-fluor-1-(2,4-difluor-fenil)-1,4-dihidro-4-okso-1,8-naftiridin-3-karbonskabes metansulfonskabes sals jauna kristaliska modifikacija

Info

Publication number
LV11619A
LV11619A LV960172A LV960172A LV11619A LV 11619 A LV11619 A LV 11619A LV 960172 A LV960172 A LV 960172A LV 960172 A LV960172 A LV 960172A LV 11619 A LV11619 A LV 11619A
Authority
LV
Latvia
Prior art keywords
naphthyridine
azabicyclo
hex
difluoro
dihydro
Prior art date
Application number
LV960172A
Other languages
English (en)
Other versions
LV11619B (en
Inventor
Lynne A Handanyan
Robert L Hendrickson
Phillip J Johnson
Thomas A Morris
Timothy Norris
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of LV11619A publication Critical patent/LV11619A/lv
Publication of LV11619B publication Critical patent/LV11619B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LVP-96-172A 1995-06-06 1996-06-04 Novel crystal form of anhydrous 7-(£1a,5a,6a|-6-amino-3-azabicyclo£3.1.0|hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt LV11619B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/007211 WO1996039406A1 (en) 1995-06-06 1995-06-06 NOVEL CRYSTAL FORM OF ANHYDROUS 7-([1α, 5α, 6α]-6-AMINO-3-AZABICYCLO[3.1.0]HEX-3-YL)-6-FLUORO-1-(2,4-DIFLUOROPHENYL)-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONIC ACID SALT

Publications (2)

Publication Number Publication Date
LV11619A true LV11619A (lv) 1996-12-20
LV11619B LV11619B (en) 1997-04-20

Family

ID=39431076

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-172A LV11619B (en) 1995-06-06 1996-06-04 Novel crystal form of anhydrous 7-(£1a,5a,6a|-6-amino-3-azabicyclo£3.1.0|hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt

Country Status (38)

Country Link
US (1) US5763454A (lv)
EP (1) EP0789697B1 (lv)
JP (1) JP3145715B2 (lv)
KR (1) KR100191989B1 (lv)
CN (1) CN1055474C (lv)
AR (1) AR002753A1 (lv)
AU (1) AU703634B2 (lv)
BG (1) BG62443B1 (lv)
BR (1) BR9602630A (lv)
CA (1) CA2223404C (lv)
CZ (1) CZ285878B6 (lv)
DE (1) DE69503066T2 (lv)
DK (1) DK0789697T3 (lv)
DZ (1) DZ2046A1 (lv)
ES (1) ES2117426T3 (lv)
FI (1) FI974441A0 (lv)
HR (1) HRP960267B1 (lv)
HU (1) HUP9601540A3 (lv)
IL (1) IL118488A (lv)
IS (1) IS4351A (lv)
LV (1) LV11619B (lv)
MA (1) MA23892A1 (lv)
NO (1) NO305599B1 (lv)
NZ (1) NZ286735A (lv)
OA (1) OA10293A (lv)
PE (1) PE38097A1 (lv)
PL (1) PL314604A1 (lv)
RU (1) RU2125571C1 (lv)
SG (1) SG54339A1 (lv)
SI (1) SI9600185A (lv)
SK (1) SK280535B6 (lv)
TN (1) TNSN96084A1 (lv)
TW (2) TW580389B (lv)
UA (1) UA44718C2 (lv)
UY (1) UY25459A1 (lv)
WO (1) WO1996039406A1 (lv)
YU (1) YU34596A (lv)
ZA (1) ZA964647B (lv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
US20020032216A1 (en) 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
US7019142B2 (en) * 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
HN1999000141A (es) * 1998-09-03 2000-06-19 Pfizer Prod Inc Procedimiento para preparar sales de trovafloxacina de adicion de acidos.
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
ES2164520B1 (es) 1999-03-16 2003-04-01 Medichem Sa "procedimiento de obtencion del polimorfo a del mesilato de doxazosina"
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
US6657061B2 (en) 2001-06-29 2003-12-02 Grayson Walker Stowell Polymorphic forms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6660864B2 (en) 2001-06-29 2003-12-09 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6388080B1 (en) 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6531603B1 (en) 2001-06-29 2003-03-11 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6596871B2 (en) 2001-06-29 2003-07-22 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6573382B2 (en) 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
CN102512364A (zh) * 2011-12-30 2012-06-27 天津市嵩锐医药科技有限公司 一种供注射用的甲磺酸阿拉曲伐沙星药物组合物
TWI608970B (zh) * 2013-01-11 2017-12-21 參天製藥股份有限公司 內塞和具備該內塞的液體收容容器、以及注口的前端構造和具備該構造的液體收容容器

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
PL166381B1 (pl) * 1989-08-16 1995-05-31 Pfizer Sposób wytwarzania nowych podstawionych kwasów 7-azabicyklochinolonokarboksylowych PL PL PL PL
KR100221386B1 (ko) * 1994-01-18 1999-09-15 디. 제이. 우드, 스피겔 알렌 제이 나프티리돈카복실산 염의 제조방법 및 중간체
GB2289674A (en) * 1994-05-23 1995-11-29 Pfizer Antibacterial naphthyridine

Also Published As

Publication number Publication date
MA23892A1 (fr) 1996-12-31
HU9601540D0 (en) 1996-07-29
UA44718C2 (uk) 2002-03-15
DE69503066T2 (de) 1998-10-15
ZA964647B (en) 1997-10-22
MX9709873A (es) 1998-03-31
DE69503066D1 (de) 1998-07-23
LV11619B (en) 1997-04-20
HUP9601540A2 (en) 1997-02-28
NZ286735A (en) 1998-01-26
SK280535B6 (sk) 2000-03-13
ES2117426T3 (es) 1998-08-01
UY25459A1 (es) 1999-11-17
RU2125571C1 (ru) 1999-01-27
WO1996039406A1 (en) 1996-12-12
FI974441A (fi) 1997-12-05
CN1055474C (zh) 2000-08-16
SG54339A1 (en) 1998-11-16
NO305599B1 (no) 1999-06-28
HRP960267B1 (en) 2000-06-30
IL118488A0 (en) 1996-09-12
HUP9601540A3 (en) 1997-05-28
CN1148596A (zh) 1997-04-30
CA2223404A1 (en) 1996-12-12
AU703634B2 (en) 1999-03-25
BR9602630A (pt) 1998-09-08
AR002753A1 (es) 1998-04-29
BG62443B1 (bg) 1999-11-30
IS4351A (is) 1996-12-07
PL314604A1 (en) 1996-12-09
HRP960267A2 (en) 1997-08-31
SK71996A3 (en) 1997-03-05
AU5474996A (en) 1996-12-19
KR970001352A (ko) 1997-01-24
PE38097A1 (es) 1997-10-10
JP3145715B2 (ja) 2001-03-12
US5763454A (en) 1998-06-09
TNSN96084A1 (fr) 2005-03-15
DK0789697T3 (da) 1998-10-19
KR100191989B1 (ko) 1999-06-15
JPH10506650A (ja) 1998-06-30
FI974441A0 (fi) 1997-12-05
CA2223404C (en) 2001-01-16
OA10293A (en) 1997-09-19
TW580389B (en) 2004-03-21
TW403751B (en) 2000-09-01
CZ162596A3 (cs) 1998-09-16
NO962321D0 (no) 1996-06-05
BG100639A (bg) 1997-02-28
SI9600185A (en) 1997-04-30
DZ2046A1 (fr) 2002-10-22
YU34596A (sh) 1999-03-04
EP0789697A1 (en) 1997-08-20
NO962321L (no) 1996-12-09
CZ285878B6 (cs) 1999-11-17
EP0789697B1 (en) 1998-06-17
IL118488A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
LV11619A (lv) 7-(Ú1a,5a,6a¾-amino-3-azabicikloÚ3.1.0¾heks-3-il)-6-fluor-1-(2,4-difluor-fenil)-1,4-dihidro-4-okso-1,8-naftiridin-3-karbonskabes metansulfonskabes sals jauna kristaliska modifikacija
FI883807A (fi) Menetelmä farmakologisesti aktiivisten 7-(3-substituoitu-1-pyrrolidinyyli)-1-syklopropyyli-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihappojohdannaisten valmistamiseksi
AU632099B2 (en) Olefinic 1h-imidazo (4,5-c)quinolin-4-amines
CA2209487A1 (en) Imidazo[4,5-c]quinoline amines
AU3261193A (en) Amino acid derivatives as paf-receptor antagonists
AP9600817A0 (en) Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.
NZ333168A (en) Process for preparing 6,7,8,9-tetrahydro-1h-imidazo[4,5-c]quinolin-4-amine derivatives
AU5005490A (en) 1h-imidazo(4,5-c)quinolin-4-amines
IL117824A0 (en) Use of imidazo [1,2-alpha] pyridine-3-acetamide derivatives
FI91529B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyrido/1,2,3-de//1,4/bentsoksatsiinijohdannaisten valmistamiseksi
AU623688B2 (en) Substituted 1,4-dihydro-4-oxo-1-pyrodinyl- (quinoline or naphthyridine) derivatives
IE813100L (en) Naphthyridine derivatives
AU5931486A (en) 6,7,8,9 - tetrahydropyrido (1,2 - a) indole derivatives
AU7463287A (en) T-butyl ergoline derivatives
AU609159B2 (en) Method of sterilizing anthers utilizing carboxylic acid derivatives
AU7220898A (en) Cytotoxic compounds: derivatives of the pyrido{2,3,4-(kl)} acridine ring system
NO177786C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater
LV5737A4 (lv) Tetrahidro-1H-piridoÚ4,3-b¾indol-1-ona atvasinajumi
AP9600851A0 (en) Novel crystal form of anhydrous 7-(1A,5A,6A) -6- amino-3- azabicyclo(3.1.0)hex-3-YL) -6- fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo1,8-naphthyridine S-3-carboxylic acid methanesulfonic acid salt
AU628045C (en) 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
GB8809176D0 (en) Pyrido(3 4-b)indole derivatives & process for their preparation
HU9701082D0 (en) Quinolin derivatives for producing 1- and 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines
YU153189A (en) Process for obtaining new pyrido/3,2,1-ij/1,3,4-benzoxadiazine salts
ATE167478T1 (de) Kristallform von wasserfreien 7-((1a,5a,6a)-6- amino-3-azabicyclo (3.1.0.) hex-3-yl)-6-fluoro-1- (2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8- naphthyridin-carbonsäure methanesulfonsäure salz
YU153089A (en) Process for obtaining new pyrido/3,2,1-ij/1,3,4-benzoxadiazine derivatives